0001593968-24-000879.txt : 20240620
0001593968-24-000879.hdr.sgml : 20240620
20240620170839
ACCESSION NUMBER: 0001593968-24-000879
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240617
FILED AS OF DATE: 20240620
DATE AS OF CHANGE: 20240620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dubovsky Filip
CENTRAL INDEX KEY: 0001977361
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26770
FILM NUMBER: 241057381
MAIL ADDRESS:
STREET 1: C/O NOVAVAX INC.
STREET 2: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NOVAVAX INC
CENTRAL INDEX KEY: 0001000694
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 222816046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 QUINCE ORCHARD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-268-2000
MAIL ADDRESS:
STREET 1: 700 QUINCE ORCHARD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
primary_01.xml
PRIMARY DOCUMENT
X0508
4
2024-06-17
0001000694
NOVAVAX INC
NVAX
0001977361
Dubovsky Filip
700 QUINCE ORCHARD ROAD
GAITHERSBURG
MD
20878
true
President, R&D
false
Common Stock
2024-06-17
4
M
false
1404
6.97
A
68017
D
Common Stock
2024-06-17
4
M
false
12500
6.09
A
80517
D
Common Stock
2024-06-17
4
S
false
12500
14.46
D
68017
D
Common Stock
2024-06-17
4
S
false
1404
14.54
D
66613
D
Stock Option (Right to Buy)
6.97
2024-06-17
4
M
false
1404
6.97
D
2033-03-07
Common Stock
1404
46324
D
Stock Option (Right to Buy)
6.09
2024-06-17
4
M
false
12500
6.09
D
2033-03-27
Common Stock
12500
37500
D
Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
/s/Mark J. Casey, Attorney-in-Fact
2024-06-20